Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)
Avalo Therapeutics (AVTX) posted FCF Margin of 24216.95% for Q4 2025, down 209.07% on a QoQ basis from 7835.42% in Q4 2024, and down 1638153.0% year-over-year from N/an in Q4 2024.
Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 24216.95% for Q4 2025.
- Quarterly FCF Margin fell 1638153.0% year-over-year to 24216.95% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10300.0% (up 82381.0% YoY) and the FY2025 annual result came in at 87288.14%, down 7616433.0% from the prior year.
- FCF Margin was 24216.95% for Q4 2025 at Avalo Therapeutics, down from 7835.42% in the prior quarter.
- Across five years, FCF Margin topped out at 38.68% in Q3 2022 and bottomed at 24216.95% in Q4 2025.
- A 5-year average of 4004.93% and a median of 1714.77% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 690081 bps — and 2025, when it slumped 1638153 bps.
- Avalo Therapeutics' FCF Margin stood at 7351.14% in 2021, then jumped by 94 bps to 450.33% in 2022, then retreated by 8 bps to 484.41% in 2023, then tumbled by 1518 bps to 7835.42% in 2024, then tumbled by 209 bps to 24216.95% in 2025.
- Business Quant data shows AVTX's FCF Margin at 24216.95% in Q4 2025, 7835.42% in Q4 2024, and 4629.32% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24,216.95% |
| Dec 31, 2024 | -7,835.42% |
| Sep 30, 2024 | -4,629.32% |
| Dec 31, 2023 | -484.41% |
| Sep 30, 2023 | -2,896.61% |
| Jun 30, 2023 | -1,714.77% |
| Mar 31, 2023 | -2,149.47% |
| Dec 31, 2022 | -450.33% |
| Sep 30, 2022 | 38.68% |
| Jun 30, 2022 | -1,212.58% |
| Mar 31, 2022 | -1,369.74% |
| Dec 31, 2021 | -7,351.14% |
| Sep 30, 2021 | -1,353.26% |
| Jun 30, 2021 | -571.89% |
| Mar 31, 2021 | -3,876.74% |
| Dec 31, 2020 | -964.46% |
| Sep 30, 2020 | -1,068.41% |
| Jun 30, 2020 | -639.39% |
| Mar 31, 2020 | -208.39% |
| Dec 31, 2019 | -42.04% |